High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

Blood. 2020 Mar 12;135(11):866-870. doi: 10.1182/blood.2019003451.

Othman Al-Sawaf^{1

2}, Esther Lilienweiss^{1

2}, Jasmin Bahlo^{1

2}, Sandra Robrecht^{1

2}, Anna-Maria Fink^{1

2}, Michaela Patz^{1

2}, Maneesh Tandon³, Yanwen Jiang⁴, William Schary⁵, Matthias Ritgen⁶, Eugen Tausch⁷, Stephan Stilgenbauer^{7

8}, Barbara Eichhorst^{1

2}, Kirsten Fischer^{1

2}, Michael Hallek^{1

9

10

11}, Karl-Anton Kreuzer^{1

2}

¹ Department I of Internal Medicine, University of Cologne, Cologne, Germany.
² Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.
³ Roche Products Limited, Welwyn Garden City, United Kingdom.
⁴ Genentech Inc, South San Francisco, CA.
⁵ AbbVie Inc, North Chicago, IL.
⁶ Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
⁷ Department III of Internal Medicine, Ulm University, Ulm, Germany.
⁸ Department for Hematology, Oncology and Rheumatology, Saarland University Medical School, Homburg/Saar, Germany.
⁹ Department I of Internal Medicine.
¹⁰ Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany; and.
¹¹ Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.

No abstract available

Publication types